Satellos Bioscience (NASDAQ: MSLE) details 2026 director election vote results
Rhea-AI Filing Summary
Satellos Bioscience Inc. reported the results of its annual shareholder meeting held virtually on June 17, 2026. Shareholders elected all nominated directors, with support levels generally very high.
Turnout was solid, with approximately 55.33% of issued and outstanding shares represented in person or by proxy. Most directors received about 99% of votes cast in favour. Stephanie Brown received 92.22% support, and Iris Loew-Friedrich received 83.76% support, while all other nominees were supported by at least 99.69% of votes cast.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Report of Voting Results regulatory
National Instrument 51-102 regulatory
management information circular regulatory
foreign private issuer regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
(Commission File No. 001-43107)
SATELLOS BIOSCIENCE INC.
(Translation of registrant’s name into English)
15 Allstate Parkway, Suite 600
Markham, Ontario, Canada, L3R 5B4
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
| Exhibit | Description |
| 99.1 | Report of Voting Results |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Satellos Bioscience Inc. | ||
| By: | /s/ Elizabeth Williams, CPA, CA | |
| Name: | Elizabeth Williams, CPA, CA | |
| Title: | Chief Financial Officer | |
Date: June 17, 2026
Exhibit 99.1
Report of Voting Results
Satellos Bioscience Inc.
In accordance with Section 11.3 of National Instrument 51-102, the following briefly describes the matters voted upon and the outcome of the votes at the annual meeting of shareholders of Satellos Bioscience Inc. (the “Company”) held virtually on June 17, 2026 (the “Meeting”). Full details of the matters are set out in the Company’s management information circular dated May 14, 2026, which is available on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov).
| 1. | By resolution passed by way of ballot, each of the nominees for election as directors was elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed. Votes at the Meeting were as follows: |
| Director | Votes For | % For | Votes Against | % Against |
| Frank Gleeson | 9,473,905 | 99.94 | 5,348 | 0.06 |
| Franklin M. Berger | 9,478,576 | 99.99 | 677 | 0.01 |
| Brian Bloom | 9,476,755 | 99.97 | 2,498 | 0.03 |
| Stephanie Brown | 8,741,404 | 92.22 | 737,849 | 7.78 |
| Selwyn Ho | 9,473,538 | 99.94 | 5,715 | 0.06 |
| Iris Loew-Friedrich | 7,939,800 | 83.76 | 1,539,453 | 16.24 |
| Geoff Mackay | 9,449,959 | 99.69 | 29,294 | 0.31 |
| Adam Mostafa | 9,450,311 | 99.69 | 28,942 | 0.31 |
| Mark Nawacki | 9,477,041 | 99.98 | 2,212 | 0.02 |
| 2. | By resolution passed by way of ballot, PricewaterhouseCoopers LLP was appointed as auditor of the Company to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration. 98.69% of the votes represented in person or by proxy at the Meeting were in favour of the appointment and 1.31% were withheld from voting. |
In total, approximately 55.33% of the issued and outstanding shares were represented in person or by proxy at the Meeting.
Yours very truly,
/s/ Liz Williams
Chief Financial Officer and Corporate Secretary